http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2393852-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8ee484f4ba9a0406b8927b5be6c4f2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9494c30f8f6cb9e15dc21e0d6895855 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-175 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 |
| filingDate | 2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15f99e05e74eab6792b83e8ff9939c2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5473f5dcfc7748555aa84f412e4b505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_120321d1a6e1aaac72d816e5c5cf8ef7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cc5c516f223bc0ebb06f5d959f95628 |
| publicationDate | 2010-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2393852-C1 |
| titleOfInvention | Method for short-term optimisation of thromboplastin formation activity in patients with arterial hypertension and impaired glucose tolerance |
| abstract | FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine, namely to cardiology and endocrinology, and concerns optimisation of thromboplastin formation activity in the patients with arterial hypertension and impaired glucose tolerance. That is ensured by the integrated treatment including graduated static and dynamic physical activity, daily swimming in a pool for at least 20 minutes, and introduction of metformin in dosage 500 mg 2 times a day and lisinopril in dosage 10 mg once a day in the morning for 1 month. ^ EFFECT: complex of specific medicines and physical activity combined with empirically prescribed length of treatment provides normalisation of thromboplastin formation that in turn reduces risk of thrombotic complications in the case patients. ^ 1 ex |
| priorityDate | 2009-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.